ATE448205T1 - Chinolin- und chinazolinderivate mit affinität für 5ht1-rezeptoren - Google Patents

Chinolin- und chinazolinderivate mit affinität für 5ht1-rezeptoren

Info

Publication number
ATE448205T1
ATE448205T1 AT07118193T AT07118193T ATE448205T1 AT E448205 T1 ATE448205 T1 AT E448205T1 AT 07118193 T AT07118193 T AT 07118193T AT 07118193 T AT07118193 T AT 07118193T AT E448205 T1 ATE448205 T1 AT E448205T1
Authority
AT
Austria
Prior art keywords
quinoline
receptors
affinity
quinazoline derivatives
quinazoline
Prior art date
Application number
AT07118193T
Other languages
English (en)
Inventor
Markus Bergauer
Barbara Bertani
Matteo Biagetti
Steven Bromidge
Alessandro Falchi
Colin Leslie
Giancarlo Merlo
Domenica Pizzi
Marilisa Rinaldi
Luigi Stasi
Jessica Tibasco
Antonio Vong
Simon Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE448205T1 publication Critical patent/ATE448205T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07118193T 2003-07-18 2004-07-15 Chinolin- und chinazolinderivate mit affinität für 5ht1-rezeptoren ATE448205T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316915.8A GB0316915D0 (en) 2003-07-18 2003-07-18 Compounds

Publications (1)

Publication Number Publication Date
ATE448205T1 true ATE448205T1 (de) 2009-11-15

Family

ID=27764115

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07118193T ATE448205T1 (de) 2003-07-18 2004-07-15 Chinolin- und chinazolinderivate mit affinität für 5ht1-rezeptoren
AT04763307T ATE389637T1 (de) 2003-07-18 2004-07-15 Chinolin- und chinazolinderivate mit affinität für rezeptoren vom 5ht1-typ

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04763307T ATE389637T1 (de) 2003-07-18 2004-07-15 Chinolin- und chinazolinderivate mit affinität für rezeptoren vom 5ht1-typ

Country Status (28)

Country Link
US (5) US7279481B2 (de)
EP (3) EP2145622A1 (de)
JP (1) JP2006528146A (de)
KR (1) KR20060041242A (de)
CN (1) CN100441571C (de)
AR (1) AR046394A1 (de)
AT (2) ATE448205T1 (de)
AU (1) AU2004263268B2 (de)
BR (1) BRPI0412695A (de)
CA (1) CA2532452A1 (de)
CY (1) CY1107974T1 (de)
DE (2) DE602004012564T2 (de)
DK (1) DK1646613T3 (de)
ES (2) ES2302543T3 (de)
GB (1) GB0316915D0 (de)
HR (1) HRP20080226T3 (de)
IL (1) IL173036A0 (de)
IS (1) IS2744B (de)
MA (1) MA27926A1 (de)
MX (1) MXPA06000716A (de)
NO (1) NO20060774L (de)
NZ (1) NZ544586A (de)
PL (1) PL1646613T3 (de)
PT (1) PT1646613E (de)
RU (1) RU2402533C2 (de)
SI (1) SI1646613T1 (de)
TW (1) TW200521115A (de)
WO (1) WO2005014552A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
BRPI0512193B8 (pt) * 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―1h―퀴나졸린―2,4―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
EP2016943B1 (de) 2007-07-19 2011-02-23 Laboratorios del Dr. Esteve S.A. Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
WO2009029308A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
ES2430940T3 (es) * 2008-02-28 2013-11-22 University Of Virginia Patent Foundation Gen del transportador de serotonina y tratamiento del alcoholismo
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2298199B1 (de) * 2008-05-06 2012-05-23 Biedermann Technologies GmbH & Co. KG Stangenförmiges Implantat, insbesondere zur dynamischen Stabilisierung der Wirbelsäule
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP2308850A1 (de) * 2009-10-06 2011-04-13 Laboratorios Del. Dr. Esteve, S.A. Heterocyclylsubstituierte Alkylaminophenyl-Derivate, ihre Herstellung und Verwendung als Arzneimittel
HUE035574T2 (en) 2010-07-02 2018-05-28 Univ Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
UA114406C2 (uk) * 2011-08-09 2017-06-12 Такеда Фармасьютікал Компані Лімітед Похідні циклопропанаміну як інгібітори lsd1
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CA2872883A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103508927A (zh) * 2012-06-25 2014-01-15 天津药物研究院 一种2-甲磺酰氨基二苯醚的制备方法
US9751885B2 (en) 2012-10-12 2017-09-05 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CA2927527C (en) 2013-11-20 2021-06-01 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof as u-opioid receptor antagonist
SG11201608340UA (en) 2014-04-11 2016-11-29 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
PL3065748T3 (pl) 2014-12-23 2018-07-31 4D Pharma Research Limited Szczep Bacteroides thetaiotaomicron i jego zastosowanie w zmniejszaniu zapalenia
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
MD3650033T2 (ro) 2015-06-15 2022-08-31 4D Pharma Res Ltd Compoziții conţinând tulpini bacteriene
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
SI3240554T1 (sl) 2015-06-15 2019-12-31 4D Pharma Research Limited, Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
AU2016357554B2 (en) 2015-11-20 2019-04-04 Cj Bioscience, Inc. Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3520801A1 (de) 2016-03-04 2019-08-07 4D Pharma Plc Zusammensetzungen mit bakteriellen blautia-stämmen zur behandlung von viszeraler überempfindlichkeit
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商4D製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
CN115813955A (zh) 2017-06-14 2023-03-21 4D制药研究有限公司 包含细菌菌株的组合物
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
MD3804737T2 (ro) 2017-06-14 2022-10-31 4D Pharma Res Limited Compoziții care conțin tulpini bacteriene
CN108047143A (zh) * 2017-12-18 2018-05-18 刘凤娟 一种用于治疗功能性胃肠病的5-羟色胺受体拮抗剂的合成方法
RS64641B1 (sr) 2018-06-27 2023-10-31 Bristol Myers Squibb Co Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
US11866430B2 (en) 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
WO2021133751A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
MX2022007130A (es) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN118308475B (zh) * 2024-03-18 2024-11-26 安徽医科大学第一附属医院 Htr1b作为胚胎发育停滞的诊断标志物和治疗靶点方面的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2641602A (en) 1950-11-29 1953-06-09 Eastman Kodak Co 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds
US3937708A (en) 1971-06-07 1976-02-10 Boehringer Ingelheim Gmbh N-phenyl-imidazolidine-1-ones
US3992537A (en) 1971-06-07 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use
US3975525A (en) 1971-06-07 1976-08-17 Boehringer Ingelheim Gmbh N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof
JPS5883677A (ja) 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US4891275A (en) * 1982-10-29 1990-01-02 Norsk Hydro A.S. Aluminum shapes coated with brazing material and process of coating
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US4891375A (en) 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd Piperazine derivatives their preparation and pharmaceutical compositions containing them
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9300195D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
AU708053B2 (en) * 1996-03-29 1999-07-29 Duphar International Research B.V. Piperazine and piperidine compounds
AU2446297A (en) 1996-04-30 1997-11-19 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
GB2312843A (en) 1996-05-07 1997-11-12 Merck & Co Inc Method of treating rheumatoid arthritis
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
EP0900792B1 (de) 1997-09-02 2003-10-29 Duphar International Research B.V Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
AU744539B2 (en) 1997-10-27 2002-02-28 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
EP1047691A1 (de) * 1997-12-12 2000-11-02 Smithkline Beecham Plc Chinolinpiperazin- und chinolinpiperidin derivate, deren herstellung und deren verwendung als kombinierte 5-ht1a, 5-ht1b und 5-ht1d rezeptor antagonisten
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
EP1106605A4 (de) 1999-06-24 2005-12-07 Toray Industries Antagonisten des andrenergen-alpha1b-rezeptors
AU1028601A (en) * 1999-11-05 2001-05-14 Smithkline Beecham Plc Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
HUP0301458A2 (hu) 2000-10-26 2003-10-28 Smithkline Beecham Plc. Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
GB0106419D0 (en) * 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0203804D0 (en) 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003272030A1 (en) 2002-11-08 2004-06-07 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
NZ549254A (en) 2004-03-10 2010-06-25 Nycomed Gmbh Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1

Also Published As

Publication number Publication date
RU2006104993A (ru) 2006-08-10
CN100441571C (zh) 2008-12-10
IL173036A0 (en) 2006-06-11
TW200521115A (en) 2005-07-01
AR046394A1 (es) 2005-12-07
EP2145622A1 (de) 2010-01-20
US20060229312A1 (en) 2006-10-12
HRP20080226T3 (en) 2008-06-30
GB0316915D0 (en) 2003-08-20
US7459456B2 (en) 2008-12-02
ES2336148T3 (es) 2010-04-08
US7732600B2 (en) 2010-06-08
KR20060041242A (ko) 2006-05-11
DE602004012564T2 (de) 2009-04-30
EP1876174A1 (de) 2008-01-09
WO2005014552A1 (en) 2005-02-17
CY1107974T1 (el) 2013-09-04
NO20060774L (no) 2006-04-06
US20090312546A1 (en) 2009-12-17
BRPI0412695A (pt) 2006-10-03
AU2004263268B2 (en) 2010-12-16
EP1876174B1 (de) 2009-11-11
ATE389637T1 (de) 2008-04-15
US20080280919A1 (en) 2008-11-13
PL1646613T3 (pl) 2008-08-29
US20100204273A1 (en) 2010-08-12
RU2402533C2 (ru) 2010-10-27
EP1646613A1 (de) 2006-04-19
CA2532452A1 (en) 2005-02-17
IS8304A (is) 2006-02-15
NZ544586A (en) 2009-05-31
AU2004263268A1 (en) 2005-02-17
CN1852896A (zh) 2006-10-25
US7592346B2 (en) 2009-09-22
ES2302543T3 (es) 2008-07-16
DE602004024141D1 (de) 2009-12-24
US7279481B2 (en) 2007-10-09
HK1089438A1 (en) 2006-12-01
IS2744B (is) 2011-08-15
US20070167423A1 (en) 2007-07-19
PT1646613E (pt) 2008-06-19
MA27926A1 (fr) 2006-06-01
DK1646613T3 (da) 2008-07-14
DE602004012564D1 (de) 2008-04-30
JP2006528146A (ja) 2006-12-14
MXPA06000716A (es) 2006-03-30
EP1646613B1 (de) 2008-03-19
SI1646613T1 (sl) 2008-08-31

Similar Documents

Publication Publication Date Title
DE602004024141D1 (de) Chinolin- und Chinazolinderivate mit Affinität für 5HT1-Rezeptoren
ATE444068T1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
NO20055649D0 (no) Substituert dihydrokinazolin med antiviale egenskaper
DE602004016839D1 (de) Cannabinoid rezeptor-liganden und ihre verwendung
IS8439A (is) Nýjar kínólín afleiður
DE602004004553D1 (de) Chinazolinderivate
DE60328735D1 (de) Chinazolinderivate
NO20054029D0 (no) Fremgangsmate for visualisering av avstander mellom bronn- og formasjonsgrenser
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
ATE392897T1 (de) Chinolinderivate als npy antagonisten
ATE413389T1 (de) Chinazolinderivate
ITMI20031127A0 (it) Anticorpi anti-hgf e loro uso
DK1613694T3 (da) Polyalkenaminer med forbedrede anvendelsesegenskaber
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
DE502005007106D1 (de) Substituierte phenylaminothiazole und ihre verwendung
DE602007004245D1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12-rezeptor
ATE500227T1 (de) Amidderivate
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE438395T1 (de) Pyrazolderivate und ihre verwendung als orexin- rezeptor-antagonisten
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602007008597D1 (de) Chinolinderivate mit 5-ht-bindenden eigenschaften
ATE402153T1 (de) Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
DE50208368D1 (de) Rinnenschuss für strebförderer mit laderampe
ATE500223T1 (de) Phenylpentadienoylderivate und ihre verwendung als par-1-antagonisten
FI20041145L (fi) Kaivo ja liitos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties